Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Gilead Sciences, Inc. NASDAQ: GILD. In a filing disclosed on December 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Gilead Sciences stock on December 24th.
Representative Marjorie Taylor Greene also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Norfolk Southern NYSE: NSC on 12/24/2024.
- Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 12/24/2024.
- Purchased $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 12/24/2024.
- Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 12/24/2024.
- Purchased $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 12/24/2024.
- Purchased $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 12/24/2024.
- Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 12/24/2024.
- Purchased $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 12/24/2024.
- Purchased $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 12/24/2024.
- Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 12/24/2024.
Gilead Sciences Trading Up 0.4 %
Gilead Sciences stock traded up $0.36 during mid-day trading on Tuesday, hitting $92.37. 3,482,458 shares of the company's stock were exchanged, compared to its average volume of 7,043,598. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $115.12 billion, a P/E ratio of 1,026.33, a PEG ratio of 2.38 and a beta of 0.18. The company's 50 day simple moving average is $91.51 and its 200-day simple moving average is $81.88.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.33%. The ex-dividend date was Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is 3,422.22%.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on GILD shares. Daiwa America raised shares of Gilead Sciences to a "hold" rating in a research report on Monday, November 18th. Bank of America restated a "buy" rating and issued a $109.00 price target on shares of Gilead Sciences in a report on Tuesday, December 10th. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Piper Sandler boosted their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Finally, Oppenheimer lifted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "outperform" rating in a report on Tuesday, December 10th. Twelve investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $96.43.
Read Our Latest Stock Analysis on GILD
Institutional Trading of Gilead Sciences
A number of hedge funds have recently modified their holdings of GILD. Principal Financial Group Inc. lifted its position in Gilead Sciences by 4.3% during the third quarter. Principal Financial Group Inc. now owns 1,451,249 shares of the biopharmaceutical company's stock worth $121,673,000 after purchasing an additional 59,181 shares during the period. Exome Asset Management LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $4,192,000. Brass Tax Wealth Management Inc. acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $242,000. Garden State Investment Advisory Services LLC bought a new position in Gilead Sciences in the third quarter valued at approximately $221,000. Finally, Franklin Resources Inc. raised its position in Gilead Sciences by 22.8% during the third quarter. Franklin Resources Inc. now owns 2,241,354 shares of the biopharmaceutical company's stock valued at $190,611,000 after purchasing an additional 416,379 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Insiders Place Their Bets
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 8,500 shares of the business's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $91.96, for a total transaction of $781,660.00. Following the completion of the transaction, the chief financial officer now owns 132,373 shares of the company's stock, valued at approximately $12,173,021.08. The trade was a 6.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 453,734 shares of company stock worth $41,902,086 over the last three months. Insiders own 0.16% of the company's stock.
About Representative Greene
Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2025. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2024 election. Marjorie Taylor Greene earned a bachelor's degree in business administration from the University of Georgia. Greene's career experience includes co-owning construction company Taylor Commercial and founding and owning a CrossFit gym.
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
